Adial Pharmaceuticals, Inc.: operating income or loss
Operating income or loss for Adial Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Adial Pharmaceuticals, Inc. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -7,799,462 | USD | 2026-03-05 | 10-K · 0001213900-26-024175 |
| 2024-01-01 | 2024-12-31 | -8,284,457 | USD | 2026-03-05 | 10-K · 0001213900-26-024175 |
| 2023-01-01 | 2023-12-31 | -6,887,947 | USD | 2025-03-04 | 10-K · 0001213900-25-019771 |
| 2022-01-01 | 2022-12-31 | -10,859,475 | USD | 2024-04-01 | 10-K · 0001213900-24-028701 |
| 2021-01-01 | 2021-12-31 | -19,288,723 | USD | 2023-03-30 | 10-K · 0001213900-23-024719 |
| 2020-01-01 | 2020-12-31 | -10,927,985 | USD | 2022-03-28 | 10-K · 0001213900-22-015562 |
| 2019-01-01 | 2019-12-31 | -8,244,900 | USD | 2021-03-22 | 10-K · 0001213900-21-017009 |
| 2018-01-01 | 2018-12-31 | -6,987,222 | USD | 2020-03-20 | 10-K · 0001213900-20-007020 |
| 2017-01-01 | 2017-12-31 | -995,286 | USD | 2019-02-19 | 10-K · 0001213900-19-002769 |
Related financial histories
- Adial Pharmaceuticals, Inc.: total assets
- Adial Pharmaceuticals, Inc.: total liabilities
- Adial Pharmaceuticals, Inc.: stockholders equity
- Adial Pharmaceuticals, Inc.: cash and cash equivalents
- Adial Pharmaceuticals, Inc.: net income or loss
- Adial Pharmaceuticals, Inc.: operating cash flow
- Adial Pharmaceuticals, Inc.: financing cash flow
- Adial Pharmaceuticals, Inc.: investing cash flow
- Adial Pharmaceuticals, Inc.: retained earnings or deficit
- Adial Pharmaceuticals, Inc.: basic weighted-average shares
- Adial Pharmaceuticals, Inc.: diluted weighted-average shares
- Adial Pharmaceuticals, Inc.: basic earnings per share
- Adial Pharmaceuticals, Inc.: diluted earnings per share
- Adial Pharmaceuticals, Inc.: share-based compensation expense
- Adial Pharmaceuticals, Inc.: current assets
- Adial Pharmaceuticals, Inc.: current liabilities
- Adial Pharmaceuticals, Inc.: current accounts payable
- Adial Pharmaceuticals, Inc.: net finite-lived intangible assets
- Adial Pharmaceuticals, Inc.: operating expenses
- Adial Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Adial Pharmaceuticals, Inc. / CIK 0001513525
- Captured
- 2026-09-20T09:13:16.139Z
- SEC response SHA-256
a18f3033034427d32ef6db390e21f05d7acd23d932b720bc7458a3fbeee3e90d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001513525.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))